Trial Profile
Renin angiotensin system blockade: diabetes nephropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Enalapril (Primary) ; Losartan (Primary)
- Indications Diabetic nephropathies; Diabetic retinopathy
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms B-RASS; RASS
- 02 Jul 2009 Results were published in the New England Journal of Medicine.
- 05 Nov 2008 New source identified and integrated (ClinicalTrials.gov record NCT00143949).
- 12 Jul 2007 Status change